POPULAR SERVICES

CONTACT SUPPORT

Biomarkers and Therapeutic Targets


CD Mitochondria is committed to the discovery of disease-specific proteins associated with mitochondrial epigenetic products, which can be used as molecular targets for new drug design and provide molecular markers for early diagnosis of diseases.

  • Mitochondria are the key to ATP production in almost all cell types.
  • Since mitochondria do not contain histone, the methylation / hydroxymethylation rate of mitochondria may be more important than histone modification.
  • The epigenetic modification sites of mtDNA mainly include the methylation of whole and some specific fragments of genes.
  • Epigenetic modification of mitochondrial specific abnormal sites can be used in clinical tumor therapy and prevention strategies of some related diseases.
  • As a new biological marker, mtDNA epigenetic products are used to detect related diseases, including cancer, neurodegenerative diseases, and age-related diseases.

Figure 1. Mitochondrial DNA. (Vito I., et al. 2013)

CD Mitochondria provides all the necessary conditions for the research of biomarkers and therapeutic targets, including software, hardware, reagents, data acquisition, analysis methods and workflow, etc., and provides a complete and comprehensive solution for the research of biomarkers and therapeutic targets.

Sevices Content

  • Collection and treatment of biological samples (body fluids, tissues, cells), sample preparation.
  • Identification of proteins and metabolites in biological samples (body fluids, tissues, cells).
  • Analysis of differential expression of disease-related proteins.
  • Identification of differences between diseased tissues or cells and control samples.
  • Analysis of proteins and their post-translational modifications under drug therapy or regulation.
  • Proteomic study on growth cycle and development process.
  • Analysis of protein post-translational modification.
  • A qualitative and quantitative study of phosphorylation and acetylation under signal transduction.
  • Detection and quantification of target proteins and verification and confirmation of biomarkers.
  • Metabolites identification and metabonomic analysis.
  • Metabolic differences between blood and urine in the disease group and the normal group.
  • Biological toxicity markers and toxicological effects of drugs.
  • Differences in lipid metabolism between tissues or cells in disease.

Sevices Flow

Our Advantages

  • Rich experience in mitochondrial epigenetics research
  • Outstanding research team
  • Unique integrated service for mitochondrial research
  • Reliable data and results
  • Rapid turnaround and cost-effective

The services provided by CD Mitochondria on mitochondrial epigenetics do not stop there. For more information, please contact us and we will be happy to answer any of your questions.

Reference

  1. Vito I., et al. (2013). “ Mitochondrial DNA methylation as a next-generation biomarker and diagnostic tool.” Molecular Genetics and Metabolism. 1(110): 25-34.
For Research Use Only. Not For Clinical Use Or Individual Users.

Online Inquiry


  •  

Contact us

  • Tel:
  • Email:

Copyright © CD Mitochondria. All rights reserved.